Procognia has developed a tag technology to create arrays of biologically related human proteins that retain their native functions in the array format, the companies said. The first array will contain wild type human p53 and its germline SNP variants.
Procognia's SNP-variant proteins will enable researchers to investigate the mechanism of cancer progression on many proteins in parallel, the company said.
Additional protein arrays, expected to launch "in the coming months," will contain "selected sets of biologically related human proteins including collections of proteins associated with key diseases including cancer and signal transduction," according to a statement.
Financial terms of the exclusive collaboration were not disclosed.
Separately, Sigma said it has declared a quarterly cash dividend of $.17 per share. The dividend is payable on Dec. 15 to shareholders of record on